How a Small and Young Foundation Catalyzed Research into a Rare Disease

Charcot-Marie Tooth disease is a rare, genetic nerve condition that affects 150,000 Americans and nearly 3 million people around the world. Though the condition was first medically recognized in 1886, it is without an approved therapy. The CMT Research Foundation has been seeking to change that by addressing barriers to the development of therapies for CMT. We spoke to Susan Ruediger, founder and CEO of CMT Research Foundation, about its efforts to catalyze drug development for CMT, what it’s done to address obstacles, and some of the partnerships it has established to advance the development of treatments and potentially a cure.